Dec 31, 2021

Zomedica Q4 2021 Earnings Report

Reported consolidated financial results for the year ended December 31, 2021.

Key Takeaways

Zomedica's total revenue for the Fourth Quarter 2021 was $4.1 million, with PulseVet contributing $4.0 million, a 66% increase over the previous year. The company ended the year with $195 million in cash and cash equivalents.

TRUFORMA® product revenue grew to $73,000 in Q4 2021, a 224% increase over Q3 2021.

PulseVet revenue grew to $4.0 million in Q4 2021, a 66% increase over Q4 2020.

Total revenue for Q4 2021 was $4.1 million, compared to $0 in 2020, with a gross margin of 73.9%.

Zomedica ended the year with cash and cash equivalents of $195 million.

Total Revenue
$4.08M
EPS
-$0.00336
Previous year: -$0.01
-66.4%
Cash and Equivalents
$195M
Previous year: $62M
+214.5%

Zomedica

Zomedica

Zomedica Revenue by Segment